Clinical features and follow-up of pediatric patients hospitalized for COVID-19

Feng Tang1, Wanjun Luo1, Xiaowen Wang1

  • 1Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.

Pediatric Pulmonology
|April 14, 2021
PubMed

Insights

This study followed pediatric COVID-19 patients, finding right lobe pneumonia and elevated creatine kinase-MB levels persisted one month post-discharge. These findings highlight potential long-term effects of coronavirus disease 2019 in children.

Area of Science:

  • Pediatric Infectious Diseases
  • Viral Pneumonia Pathogenesis
  • Clinical Manifestations of COVID-19

Background:

  • Coronavirus disease 2019 (COVID-19) has impacted global health, with pediatric cases requiring specific clinical attention.
  • Understanding the clinical course and long-term sequelae in children is crucial for effective management.

Purpose of the Study:

  • To summarize clinical features and 1-month follow-up observations of pediatric patients hospitalized with COVID-19.
  • To analyze the association between lung involvement and clinical outcomes.

Main Methods:

  • Retrospective analysis of 127 pediatric patients hospitalized with COVID-19.
  • Inclusion of clinical data, serum SARS-CoV-2 IgG/IgM tests, RT-PCR, lung CT scans, and laboratory tests.
  • 1-month follow-up assessments for clinical manifestations and laboratory markers.

Main Results:

  • Right lobe pneumonia was observed in 22% of patients at 1-month follow-up.
  • Persistently elevated serum creatine kinase (CK) and creatine kinase-myocardial band (CK-MB) levels were noted.
  • Four patients retested positive for SARS-CoV-2 at follow-up.

Conclusions:

  • Lung lobe involvement in COVID-19 correlates with the persistence of pneumonia, elevated CK-MB, and body temperature.
  • Right lobe pneumonia and elevated CK-MB may be indicators of prolonged recovery in pediatric COVID-19 patients.
Abstract

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
554
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
558
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
70
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
466
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.5K